Wallace, John L. 
; Nagy, Peter ; Feener, Troy D.; Allain, Thibault ; Ditrói, Tamás; Vaughan, David J.; Muscará, Marcelo Nicolás (Orientador) ; De Nucci, Gilberto ; Buret, Andre G.
Source: British Journal of Pharmacology. Unidade: ICB
Subjects: FARMACOLOGIA, ENSAIO CLÍNICO, ANTI-INFLAMATÓRIOS, SISTEMA GASTROINTESTINAL, MEDICAMENTO, ANALGÉSICOS, FÁRMACOS GASTRINTESTINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WALLACE, John L. et al. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, n. 4, p. 769-777, 2020Tradução . . Disponível em: https://doi.org/10.1111/bph.14641. Acesso em: 06 nov. 2024.APA
Wallace, J. L., Nagy, P., Feener, T. D., Allain, T., Ditrói, T., Vaughan, D. J., et al. (2020). A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, ( 4), 769-777. doi:10.1111/bph.14641NLM
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1111/bph.14641Vancouver
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1111/bph.14641
